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Major histocompatibility complex (MHC) class II pro-
teins are cell-surface heterodimeric glycoproteins that
function in the initiation of acquired immune responses.
In antigen-presenting cells, antigenic peptides are loaded
onto MHC class II molecules in a process that depends
on the class II invariant chain and another accessory
protein, human leukocyte antigen (HLA-DM). This pro-
cess is completed in a specialized, post-Golgi intracel-
lular compartment, the MHC class II compartment
(MIIC; Peters et al. 1991), where peptides with the high-
est affinity for the MHC class II proteins are selected
for presentation (Denzin and Cresswell 1995). Subse-
quently, the MHC-peptide complex is transported to the
surface where it can interact with antigen-specific CD4
T-helper cells, initiating an immune response.MHCclass
II molecules are expressed in a limited subset of immune
cells, including B cells, macrophages, activated T cells,
thymic epithelial cells, and dendritic cells. MHC class II
genes may also be induced in many other cell types by
the cytokine interferon-g (IFN-g). Induction by IFN-g
may allow presentation of antigens to the immune sys-
tem by nonimmune cells.
Because of this intimate involvement in immune re-
sponses, aberrant expression of MHC class II genes
could potentially lead to or sustain autoimmune disor-
ders, tumor growth, or failure to mount an immune
response. Lack of expression of MHC class II genes re-
sults in a severe combined immunodeficiency, called bare
lymphocyte syndrome (BLS). Patients with BLS are 5%
of all cases of severe combined immunodeficiency (El-
hasid and Etzioni 1996). Cell lines derived from these
patients and a collection of lab-generated cell lines that
share the same characteristics as BLS-derived cells have
provided unique tools for elucidating the regulation of
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MHC class II genes. This review will focus on the mo-
lecular basis for BLS and on how understanding the
genetics of this system has provided the current models
of MHC class II gene regulation.
MHC Class II Genes
MHC class II genes are located on the short arm of
chromosome 6. TheMHC class II locus encodes separate
a and b chains for each of the three isotypes: HLA-DR,
HLA-DQ, and HLA-DP. Driving the expression of these
isotypes—and the expression of other gene products that
are involved in antigen presentation—is a conserved up-
stream cis-acting regulatory region that coordinately reg-
ulates their expression.
This regulatory region consists of fourmajor elements:
the W, X1, X2, and Y boxes. Maximal expression in B
lymphocytes and during IFN-g induction requires the
presence of all these elements (reviewed by Boss 1997).
The W box is the least fully characterized of the four
elements, but the DNA-binding factor regulatory-factor
X (RFX; discussed extensively below) has been suggested
to interact with this region. RFX and the X2-
box–binding protein (X2BP), recently identified as the
cAMP response-element–binding protein (CREB), bind
to the X1 and X2 boxes, respectively (Boss 1997; Mo-
reno et al. 1999). The Y box, an inverted CCAAT box,
is bound by the heterotrimeric factor nuclear-factor y
(NF-Y). These three DNA-binding factors are required,
but are not alone sufficient, for MHC class II expression.
A fourth factor, the class II transactivator (CIITA),which
does not appear to bind DNA (Steimle et al. 1993), is
also required. CIITA is proposed to interact with the
DNA-bound factors RFX, CREB, and NF-Y at the class
II promoter and to use its acidic activation domain to
activate transcription.
BLS and MHC Class II Expression
BLS is a rare autosomal recessive disease characterized
by severe combined immunodeficiency. More than 40
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cases have been diagnosed since its description (Griscelli
et al. 1989). Although some patients show very low lev-
els of MHC class II cell-surface expression, most patients
do not express MHC class II proteins or mRNA in their
cells. Patients can also vary in the levels of expression
of MHC class I proteins, which are expressed on vir-
tually all cell types. Patients with BLS usually present in
the first year of life with infections in the respiratory
system and the gastrointestinal tract. In addition, viral
infections are extremely dangerous, and, as a result of
intestinal infections, affected children exhibit protracted
diarrhea, severe malabsorption, and failure to thrive.
The humoral immune response in these patients is se-
verely impaired, varying from panhypogammaglobuli-
nemia to reduction in one or two of the Ig isotypes (Klein
et al. 1993). The prognosis for these patients is very poor,
and most do not reach puberty (Elhasid and Etzioni
1996). The current treatment for BLS includes regular
intravenous immunoglobulin support and prophylactic
antibiotics (Klein et al. 1993; Elhasid and Etzioni 1996).
The only effective long-term treatment is a bone-marrow
transplant. The prognosis for post-transplant BLS pa-
tients depends on the age of the patient, with younger
patients responding more favorably. Infection as a result
of the immune suppression after transplant causes many
of the complications associated with recovery (Elhasid
and Etzioni 1996).
Haplotyping of family members of patients with BLS
shows that the MHC locus segregates independently of
the BLS phenotype (de Preval et al. 1985), suggesting,
as proposed by Gladstone and Pious (1980), that one
or more transacting factors that regulate expression of
MHC class II genes are mutated in this syndrome. To
determine how many genes are involved in BLS, somatic
cell-fusion experiments were performed between the dif-
ferent patient cell lines and in vitro–generated cell lines.
Four complementation groups—A, B, C, and D—have
been defined (Benichou and Strominger 1991; Seidl et
al. 1992), demonstrating that, although patients with
BLS share a similar phenotype, the genetic basis of the
disease is heterogeneous (table 1).
This complementation analysis provided a powerful
system with which to identify the defective genes in two
of the complementation groups. Further clues about the
different molecular defects in the various complemen-
tation groups came from in vitro and in vivo studies of
protein-DNA interactions in the MHC class II gene pro-
moters. In a variety of DNA-binding assays, X2BP/
CREB and NF-Y binding is seen, both in wild-type cells
and in all complementation groups of BLS cells. How-
ever, two patterns emerged with regard to RFX binding.
RFX activity was present in BLS group A cells but not
in cells from groups B–D, suggesting that RFX activity
may be encoded in three or more distinct genes. Fur-
thermore, in vivo footprint analysis reveals two patterns
that correlate with RFX activity (Kara and Glimcher
1991, 1993), corresponding to the X1-, X2-, and Y-box
regions of the MHC class II promoters. Both wild-type
and BLS group A cells contain fully occupied promoters,
but the other BLS groups show no binding to X1, X2,
or Y elements.
Complementation Group A: CIITA Deficiency
Defects in CIITA are common to all cells in comple-
mentation group A—the first of the BLS groups to be
characterized at the molecular level.MHC2TA, the gene
that encodes CIITA, maps to 16p13. CIITA was cloned
by cDNA complementation in an in vitro–generated cell
line (Steimle et al. 1993). The N-terminal portion of the
1,130 amino acid CIITA protein carries a transcrip-
tional-activation domain (Riley et al. 1995; Zhou and
Glimcher 1995). The finding that CIITA does not bind
to DNA (Steimle et al. 1993) is consistent with the in
vivo footprinting results showing a fully occupied pro-
moter region in BLS group A cells and suggests that
CIITA interacts with the DNA-bound W-, X-, and Y-
box factors. Indeed, CIITA appears to act as a master
regulator, because it is developmentally regulated in B
cells (Chang et al. 1992) and because it is induced by
IFN-g (Steimle et al. 1994) in nonlymphoid cells prior
to their induction of MHC class II genes.
The cloning of MHC2TA has allowed for mutation
analysis of cells in complementation group A, whether
from cultured mutant cell lines or from the two known
patients in this group, patient BCH and patient BLS-2.
Mutations in the BLS group A–like cell line, RJ2.2.5,
comprise a complete loss of one allele (Steimle et al.
1993) and an internal deletion of 1,811 bp in the second
allele (Brown et al. 1995). Patient BCH is a compound
heterozygote with a GrT transversion that results in a
nonsense mutation and a severely truncated protein in
one allele (Bontron et al. 1997). The second allele con-
tains a GrA transition in a splice-donor sequence lead-
ing to an 84 bp in-frame deletion of an exon. Both mu-
tations completely inactivate the CIITA protein. Patient
BLS-2 is homozygous for a GrA transition in a splice-
donor sequence that results in a 72 bp in-frame deletion
(Steimle et al. 1993). This deletion removes a 5 amino
acid nuclear-localization sequence, rendering CIITA un-
able to translocate to the nucleus (Cressman et al. 1999).
Two CIITA knockout mice have been generated
(Chang et al. 1996; Williams et al. 1998). Both mutant
mouse strains display a phenotype similar to that of
patients with BLS in that they lack MHC class II mol-
ecules on their antigen-presenting cells and have a re-
duced number of peripheral CD4 T cells. Interestingly,
both mutant strains have residual MHC class II expres-
sion on a subset of thymic epithelial cells and on a subset
Table 1
Mutations in BLS Genes
BLS
Group
and Gene
(Location)
Cell and
Patient Lines Genotype Mutation(s) Result of Mutation
MHC
Levels
A:
CIITA (16p) BLS-2 H GrA at s.d. 72 bp in-frame D of exon encoding a.a. 940–963
that contains nuclear localization signal ND
BCH CH GrT; GrA at s.d. GAA (Glu381)rTAA (stop);
84 bp in-frame D (a.a 1079–1106) ND
RJ2.2.5a CH 1,811-bp D in mRNA completely deleted Frameshift; complete null ND
B:
RFX-B or
RFX-ANK (19p12)
Bequit (Ab), Nacera (Nh),
and Ramia (RA)b
H 26-bp D in s.a. of exon 6 Frameshift ND
BLS-1 H 58-bp D in s.d. of exon 6 Frameshift ND
EBA H GrT in exon 5 GAG (Glu102)rTAG (stop) Low
FZA H TrC in exon 8 CTG (Leu195)rCCG195 (Pro) Low
C:
RFX5 (1q21.1-q21.3) Ro H C1032 rT1032 CGA (Arg294)rTGA (stop) Low
SJO CH GrA in the s.a. of exon 5;
other allele is not defined
Use of a cryptic s.a. at 5 results
in 5-bp D and frameshift; not expressed ND
THF, EVFc H GrA at  5 s.d. of exon 2 Use of a cryptic s.d. at 10
results in 10-bp D and frameshift ND
OSE H GrA in the s.a. of exon 4 Use of a cryptic s.a. at 4
results in 4-bp D and frameshift ND
SSI H C1122rT CAG (Gln321)rTAG (stop) ND
D:
RFXAP (13q) ABI, AkOb H C279rT279 CAG (Gln55)rTAG (stop) Low
DA, ZM, SSb H DG484 Frameshift Low
6.1.6a CH G insertion at 418 bp; G insertion at 508 bp Frameshift; frameshift Low
ShA, ShGc H 7-bp insertion at 151 as a result of duplication of 144–150 bp Frameshift Low
NOTE.—See text for references. Abbrieviations: H  homozygous; CH  compound heterozygous; s.a.  splice acceptor; s.d. splice donor; D  deletion; and ND  not detectable.
a Experimentally derived mutant cell lines.
b Unrelated patients.
c Siblings or cousins.
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of dendritic cells. Mice of both groups show a reduction,
but not a complete loss, in their expression of the in-
variant chain and of H-2M (the mouse orthologue of
HLA-DM; Chang et al. 1996; Williams et al. 1998). A
reduction in global MHC class I expression that is ob-
served in some human patients was not detected in either
mouse. Unexpectedly, cells from both CIITA-deficient
mouse strains up-regulate MHC class I when treated
with IFN-g. However, the level of IFN-g–induced MHC
class I was definitively lower in the C2ta/ mouse, de-
scribed by Williams et al. (1998), than in wild-typemice.
Thus, although these knockout mice do not provide a
perfect model for BLS, they do follow some of the var-
iation that has been documented in patients with BLS.
Importantly, these studies suggest CIITA-independent
mechanisms of MHC class II regulation that require
investigation.
Complementation Group B: RFX-B/ANK Deficiency
Patient-derived cell lines lacking RFX binding to
MHC class II promoters are represented in the comple-
mentation groups B, C, and D. Co-immunoprecipitation
experiments with the RFX5 subunit of RFX identified
two associated proteins, with apparent molecular
weights of 41 and 33 kDa (Moreno et al. 1997). The
co-immunoprecipitation of p41 requires the presence of
p33 and vice versa, suggesting that RFX5 and the two
associated subunits form a tight complex. The study by
Moreno et al. (1997) also predicted that BLS groups B,
C, and D would be affected in the genes encoding the
three subunits of RFX.
The largest of the four BLS complementation groups
is group B, with 124 patients (Fondaneche et al. 1998).
The defective gene in this group was cloned by isolating
the RFX complex, sequencing the 33-kDa protein, and
isolating the cDNA on the basis of the protein sequence.
The gene, which maps to 19p12, was termed “RFX-B”
(Nagarajan et al. 1999) or “RFX-ANK” (Masternak et
al. 1998), the latter name indicating that the gene protein
contains three ankyrin repeats, domains that typically
mediate protein-protein interactions. These regions
could be involved in RFX-complex formation and/or
interaction with other DNA-bound factors, such as
X2BP/CREB or NF-Y. BLS group B patients display the
greatest diversity of disease alleles. BLS group B–derived
cell lines Bequit, Nacera, and Ramia carry a common
homozygous deletion of 26 bp that removes the splice-
acceptor region of exon 6, resulting in the deletion of
exon 6, and a frameshift that results in a truncated pro-
tein (Nagarajan et al. 1999; Masternak et al. 1998) (ta-
ble 1). These three patients are unrelated but come from
the same geographical area of North Africa, suggesting
a common ancestor for this allele. Patient BLS-1 has a
58-bp deletion in the splice-donor region of exon 6, re-
sulting in a frameshift (Masternak et al. 1998). Patient
EBA has a nonsense mutation in exon 5, resulting in a
truncated protein (U. Nagarajan and J. Boss, unpub-
lished data). Patient FZA has a homozygous point mu-
tation, changing a conserved leucine in the third ankyrin
repeat to a proline in exon 8 (U. Nagarajan and J. Boss,
unpublished data). Cell lines from patient EBA and pa-
tient FZA can be induced to express low levels of MHC
class II genes, which may be due to an alternatively
spliced product or to some residual activity of the variant
protein.
Complementation Group C: RFX5 Deficiency
Complementation group C mutations are in the gene
encoding RFX5, which maps to 1q21. RFX5 was the
first of the RFX subunits to be identified genetically.
RFX5was cloned by complementation of theMHCclass
II–negative cell line of patient SJO (Steimle et al. 1995).
At 66 kDa and 616 aa, RFX5 is the largest of the RFX
subunits and is the only subunit to contain a known
DNA-binding motif. Patient Ro and patient SSI both
carry nonsense mutations, at position 1032 and 1122,
respectively (Steimle et al. 1995; Peijnenburg et al.
1999). The remaining patients all carry GrA transitions
at splice junctions that result in the use of cryptic splice
sites and premature truncations; these splice junctions
occur in exon 5 in SJO cells (Steimle et al. 1995), in
exon 2 in patient THF and patient EVF cells (Villard et
al. 1997b), and in exon 4 in patient OSE cells (Peijnen-
burg et al. 1999).
Clausen et al. (1998) have generated an Rfx5 knock-
out mouse and have determined that the phenotype re-
capitulates many aspects of human BLS. Rfx5/ mice
have a severe immunodeficiency because of absence of
CD4 T cells and a lack of MHC class II molecules on
resting B cells and macrophages. As observed in C2ta/
 mice, MHC class II expression is present on dendritic
cells, and invariant chain and H2-M were reduced but
not absent. In contrast to the C2ta/ mice, however,
strong MHC class II expression was detected in thymic
medullary epithelial cells and activated B cells. The find-
ing of RFX5-independent MHC class II expression is
intriguing and suggests a novel mechanism ofMHC class
II gene control.
Complementation Group D: RFXAP Deficiency
The gene mutated in complementation group D is
RFXAP, which maps to 13q14. This gene was cloned
by isolation of the RFX complex and sequencing of the
41-kDa protein. With its cloning, the question of
Figure 1 Model of MHC class II gene regulation. Three stages of regulation are represented. The sequence-specific transcription factors that interact with the X1-, X2-, and Y-box elements
assemble in all cells. Activation of gene expression occurs in two parts. The first is through the expression of CIITA and its interaction(s) with the DNA-bound factors. CIITA may interact with
components of the general-transcription complex, including TATA-binding protein and its associated factors. The second part is provided by general coactivators of transcription (represented by CBP
in this model) that augment activator-dependent transcription. Regulation of expression of MHC class II genes can occur at any of these steps, as depicted by the arrows and stops.
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whether a fourth complementation group existed was
resolved. The question arose from the fact that cell line
6.1.6—the BLS group D experimental cell linemost stud-
ied (Gladstone and Pious 1978)—as well as the patient
cell lines, showed slight MHC class II expression. How-
ever, this expression did not lead to fully functional
MHC class II proteins, since the patients exhibited BLS
symptoms. Patient ABI (Villard et al. 1997a) and patient
AkO (Fondaneche et al. 1998) carry, in homozygous
form, a CrT transition that results in a premature stop
codon and truncated protein. Patient ZM, patient SS
(Fondaneche et al. 1998), and patient DA (Durand et
al. 1997) have a deletion of a G at position 484 that
causes a frameshift and premature stop codon. Patient
ShA and pateint ShG, who are cousins, have a 7-bp
insertion (duplication) at bp 151 that also results in a
frameshift and premature stop codon (Fondaneche et al.
1998). Although both RFX-B and RFX5make sequence-
specific contacts with the X1 box, RFXAP binds at many
positions (Westerheide and Boss 1999). The role that
RFXAP plays in the RFX complex remains to be deter-
mined, but its multiple contacts with the X1 box may
indicate that it helps to stabilize the binding of the RFX
complex to specific DNA sequences.
Model of Class II Regulation
Figure 1 illustrates the current model of MHC class
II gene regulation and the role of the BLS proteins. The
RFX subunits X2BP/CREB and NF-Y are expressed in
a ubiquitous manner, although their levels may vary be-
tween cell types. If present in high enough concentra-
tions, these factors form an extremely stable complex
on the X- and Y-box–regulatory region, both in vivo
and in vitro. This complex is inactive in the absence of
CIITA, a factor that is constitutively expressed in B lym-
phocytes and other antigen-presenting cells, and that is
inducible by IFN-g in most other cell types (Steimle et
al. 1994). The N-terminal–activation domain of CIITA
most likely interacts with the X- and Y-box factors to
activate transcription (Riley et al. 1995; Zhou and
Glimcher 1995). CIITA may also stabilize the binding
of the RFX-CREB-NF–Y complex to DNA in cells in
which the concentration of the latter factors is limiting
(Moreno et al. 1997; Wright et al. 1998). Kretsovali et
al. (1998) and Fontes et al. (1999) showed that the his-
tone acetyltransferase CREB-binding protein can bind
to CIITA, perhaps allowing the assembled class II tran-
scription factor–complex to open chromatin for more
efficient transcription and factor binding. Both CIITA
and RFX have been found to be involved in the IFN-g
induction of MHC class I genes (Gobin et al. 1997,
1998; Martin et al. 1997), suggesting that the control
of antigen presentation is an ancient system that may
have existed prior to the divergence of MHC class I and
class II genes.
Conclusion
The analysis of BLS has provided genetic proof that
the RFX complex and CIITA are integral components
of MHC class II expression. The cooperative binding of
RFXwith X2BP/CREB andNF-Y has substantiated their
roles in the assembly and regulation of the class II pro-
moter. Thus, this unfortunate disorder has provided a
unique set of tools to unravel an important aspect of the
control of the immune response: control of antigen pro-
cessing and presentation. Future work will no doubt
focus on how the regulatory complex assembles, addi-
tional components that may be required for activation,
possible treatments for patients with BLS, and phar-
maceuticals that can control the assembly and activation
of these factors for use in immune-based therapies.
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